Multiple Onychopapillomas and BAP1 Tumor Predisposition Syndrome.

IF 11.5 1区 医学 Q1 DERMATOLOGY
Alexandra Lebensohn, Azam Ghafoor, Luke Bloomquist, Michael C Royer, Leslie Castelo-Soccio, Kelli Karacki, Olanda Hathaway, Tenin Maglo, Cathy Wagner, Maria G Agra, Andrew M Blakely, David S Schrump, Raffit Hassan, Edward W Cowen
{"title":"Multiple Onychopapillomas and BAP1 Tumor Predisposition Syndrome.","authors":"Alexandra Lebensohn, Azam Ghafoor, Luke Bloomquist, Michael C Royer, Leslie Castelo-Soccio, Kelli Karacki, Olanda Hathaway, Tenin Maglo, Cathy Wagner, Maria G Agra, Andrew M Blakely, David S Schrump, Raffit Hassan, Edward W Cowen","doi":"10.1001/jamadermatol.2024.1804","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>BRCA1-associated protein (BAP1) tumor predisposition syndrome (TPDS) is a cancer genodermatosis associated with high risk of uveal and cutaneous melanoma, basal cell carcinoma, and multiple internal malignant neoplasms, including mesothelioma and renal cell carcinoma. Early detection of the syndrome is important for cancer surveillance and genetic counseling of family members who are at risk.</p><p><strong>Objective: </strong>To determine the prevalence of nail abnormalities in individuals with pathogenic germline variants in BAP1.</p><p><strong>Design, setting, and participants: </strong>In this prospective cohort study, individuals who were known carriers of pathogenic BAP1 germline variants were consecutively enrolled between October 10, 2023, and March 15, 2024. Dermatologic evaluation for nail abnormalities was performed, including a history of nail abnormalities and associated symptoms, physical examination, medical photography, and nail biopsy for histopathology. This was a single-center study conducted at the National Institutes of Health Clinical Center.</p><p><strong>Main outcomes and measures: </strong>Primary outcomes were the prevalence and spectrum of nail changes and histopathologic characterization.</p><p><strong>Results: </strong>Among 47 participants (30 female [63.8%]; mean [SD] age, 46.4 [15.1] years) ranging in age from 13 to 72 years from 35 families, nail abnormalities were detected in 41 patients (87.2%) and included leukonychia, splinter hemorrhage, onychoschizia, and distal nail hyperkeratosis. Clinical findings consistent with onychopapilloma were detected in 39 patients (83.0%), including 35 of 40 individuals aged 30 years or older (87.5%). Nail bed biopsy was performed in 5 patients and was consistent with onychopapilloma. Polydactylous involvement with onychopapillomas was detected in nearly all patients who had nail involvement (38 of 39 patients [97.4%]).</p><p><strong>Conclusions and relevance: </strong>This study found that BAP1 TPDS was associated with a high rate of nail abnormalities consistent with onychopapillomas in adult carriers of the disease. Findings suggest that this novel cutaneous sign may facilitate detection of the syndrome in family members who are at risk and patients with cancers associated with BAP1 given that multiple onychopapillomas are uncommon in the general population and may be a distinct clue to the presence of a pathogenic germline variant in the BAP1 gene.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":null,"pages":null},"PeriodicalIF":11.5000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11102040/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamadermatol.2024.1804","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Importance: BRCA1-associated protein (BAP1) tumor predisposition syndrome (TPDS) is a cancer genodermatosis associated with high risk of uveal and cutaneous melanoma, basal cell carcinoma, and multiple internal malignant neoplasms, including mesothelioma and renal cell carcinoma. Early detection of the syndrome is important for cancer surveillance and genetic counseling of family members who are at risk.

Objective: To determine the prevalence of nail abnormalities in individuals with pathogenic germline variants in BAP1.

Design, setting, and participants: In this prospective cohort study, individuals who were known carriers of pathogenic BAP1 germline variants were consecutively enrolled between October 10, 2023, and March 15, 2024. Dermatologic evaluation for nail abnormalities was performed, including a history of nail abnormalities and associated symptoms, physical examination, medical photography, and nail biopsy for histopathology. This was a single-center study conducted at the National Institutes of Health Clinical Center.

Main outcomes and measures: Primary outcomes were the prevalence and spectrum of nail changes and histopathologic characterization.

Results: Among 47 participants (30 female [63.8%]; mean [SD] age, 46.4 [15.1] years) ranging in age from 13 to 72 years from 35 families, nail abnormalities were detected in 41 patients (87.2%) and included leukonychia, splinter hemorrhage, onychoschizia, and distal nail hyperkeratosis. Clinical findings consistent with onychopapilloma were detected in 39 patients (83.0%), including 35 of 40 individuals aged 30 years or older (87.5%). Nail bed biopsy was performed in 5 patients and was consistent with onychopapilloma. Polydactylous involvement with onychopapillomas was detected in nearly all patients who had nail involvement (38 of 39 patients [97.4%]).

Conclusions and relevance: This study found that BAP1 TPDS was associated with a high rate of nail abnormalities consistent with onychopapillomas in adult carriers of the disease. Findings suggest that this novel cutaneous sign may facilitate detection of the syndrome in family members who are at risk and patients with cancers associated with BAP1 given that multiple onychopapillomas are uncommon in the general population and may be a distinct clue to the presence of a pathogenic germline variant in the BAP1 gene.

多发性 Onychopapillomas 和 BAP1 肿瘤易感综合征。
重要性:BRCA1 相关蛋白(BAP1)肿瘤易感综合征(TPDS)是一种癌症基因遗传病,与葡萄膜和皮肤黑色素瘤、基底细胞癌以及包括间皮瘤和肾细胞癌在内的多种体内恶性肿瘤的高风险相关。早期发现该综合征对癌症监测和高危家庭成员的遗传咨询非常重要:目的:确定BAP1致病性种系变异个体中指甲异常的患病率:在这项前瞻性队列研究中,2023 年 10 月 10 日至 2024 年 3 月 15 日期间连续招募了已知的 BAP1 基因变异致病性携带者。研究人员对指甲异常进行了皮肤学评估,包括指甲异常病史和相关症状、体格检查、医学摄影和指甲活检组织病理学检查。这是一项在美国国立卫生研究院临床中心进行的单中心研究:主要结果和测量方法:主要结果是指甲变化的发生率和范围以及组织病理学特征:在来自35个家庭、年龄从13岁到72岁不等的47名参与者(30名女性[63.8%];平均[标码]年龄为46.4[15.1]岁)中,有41名患者(87.2%)被检测出指甲异常,包括白斑病、劈裂出血、甲癣和远端甲过度角化。39名患者(83.0%)的临床表现与甲软骨瘤相符,其中40人中有35人年龄在30岁或以上(87.5%)。对 5 名患者进行了甲床活检,结果与甲软骨瘤一致。几乎所有指甲受累的患者(39 例患者中有 38 例[97.4%])都发现了甲多发性受累:本研究发现,BAP1 TPDS 与成年带原者指甲异常率较高有关,与甲沟乳头状瘤一致。研究结果表明,鉴于多发性甲状软骨瘤在普通人群中并不常见,这种新的皮肤征象可能有助于在高危家庭成员和与 BAP1 相关的癌症患者中发现该综合征,并可能成为 BAP1 基因致病性种系变异存在的明显线索。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JAMA dermatology
JAMA dermatology DERMATOLOGY-
CiteScore
14.10
自引率
5.50%
发文量
300
期刊介绍: JAMA Dermatology is an international peer-reviewed journal that has been in continuous publication since 1882. It began publication by the American Medical Association in 1920 as Archives of Dermatology and Syphilology. The journal publishes material that helps in the development and testing of the effectiveness of diagnosis and treatment in medical and surgical dermatology, pediatric and geriatric dermatology, and oncologic and aesthetic dermatologic surgery. JAMA Dermatology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications. It is published online weekly, every Wednesday, and in 12 print/online issues a year. The mission of the journal is to elevate the art and science of health and diseases of skin, hair, nails, and mucous membranes, and their treatment, with the aim of enabling dermatologists to deliver evidence-based, high-value medical and surgical dermatologic care. The journal publishes a broad range of innovative studies and trials that shift research and clinical practice paradigms, expand the understanding of the burden of dermatologic diseases and key outcomes, improve the practice of dermatology, and ensure equitable care to all patients. It also features research and opinion examining ethical, moral, socioeconomic, educational, and political issues relevant to dermatologists, aiming to enable ongoing improvement to the workforce, scope of practice, and the training of future dermatologists. JAMA Dermatology aims to be a leader in developing initiatives to improve diversity, equity, and inclusion within the specialty and within dermatology medical publishing.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信